Nymox Says AlzheimAlert Diagnostic Will Be Considered By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Nymox Pharmaceutical aspires to sell kit versions of its AlzheimAlert "home brew" test for Alzheimer's to qualified laboratories and hospitals in the U.S., pending a successful advisory panel review and subsequent PMA approval